PDL1 inhibitors may be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database
We confirm the association between ICI treatment and AR. Notably, PDL1 inhibitors showed surprisingly low AR reports compared to CTLA4 and PD1 inhibitors. Further prospective studies are warranted to confirm whether PDL1 inhibitors indeed reduce AR risk compared to other ICI.
Authors
- Charles‐Hugo Marquette (ORCID: https://orcid.org/0000-0002-0846-9941)
- Delphine Borchiellini (ORCID: https://orcid.org/0000-0002-8204-8301)
- Alexandre Destère (ORCID: https://orcid.org/0000-0001-6147-9201)
- A Sicard (ORCID: https://orcid.org/0000-0003-3427-3894)
- Henri Montaudié (ORCID: https://orcid.org/0000-0002-0528-4829)
- Marine Andreani
- Alexandre Olivier Gérard (ORCID: https://orcid.org/0000-0001-6591-6966)
- Fanny Rocher (ORCID: https://orcid.org/0000-0002-5835-6224)
- Diane Merino (ORCID: https://orcid.org/0000-0001-7669-2339)
- Clément Gosset
- Milou-Daniel Drici
- Jonathan Benzaquen
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Côte d'Azur (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Laboratoire de PhysioMédecine Moléculaire (FR)
- Centre Méditerranéen de Médecine Moléculaire (FR)
- Centre Antoine Lacassagne (FR)
- Institut de Pharmacologie Moléculaire et Cellulaire (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1514033
- Citations
- 4
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 5.58